United States Liquid Biopsy Market

Market Overview:

United States liquid biopsy market size reached USD 563.6 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,775.8 Million by 2033, exhibiting a growth rate (CAGR) of 13.6% during 2025-2033. The rising need for personalized treatments among individuals across the country is propelling the adoption of this method to analyze the genetic mutations in an efficient manner, which is primarily driving the market growth.

Liquid biopsy is a non-invasive diagnostic method that entails examining a patient's blood or other bodily fluids to identify genetic material or biomarkers originating from tumors. This technique holds great promise for cancer diagnosis, monitoring, and tailoring treatment to individual patients. The underlying principle is that cancer cells consistently release genetic material, such as DNA, RNA, and proteins, into the blood or other bodily fluids. Through the analysis of these circulating tumor biomarkers, liquid biopsy tests can identify and track cancer development, assess the effectiveness of treatment, and detect any remaining disease or recurrence. In comparison to the conventional tissue biopsy, which involves extracting a tissue sample from the tumor site for analysis, liquid biopsy offers several advantages. It is less invasive, faster, and can be repeated over time, facilitating real-time tracking of tumor changes and treatment responses. Additionally, it aids in pinpointing specific genetic mutations or alterations in tumors, providing valuable information for personalized treatment decisions and ultimately enhancing patient outcomes.

United States Liquid Biopsy Market Trends:

The United States liquid biopsy market is experiencing rapid growth and significant advancements as a groundbreaking diagnostic tool in the field of cancer detection and monitoring. This minimally invasive technique involves the analysis of blood or other bodily fluids to identify genetic material or biomarkers originating from tumors, presenting a paradigm shift in cancer diagnostics. Additionally, the market's expansion is fueled by the increasing recognition of liquid biopsy's potential for early cancer detection, monitoring treatment responses, and guiding personalized therapeutic approaches. Besides this, its advantages over traditional tissue biopsy, including reduced invasiveness, quicker procedures, and the ability for repeated testing over time, have also contributed to its widespread adoption. Furthermore, the United States liquid biopsy market is characterized by a competitive landscape with numerous companies actively contributing to research, development, and commercialization of this method. As the demand for precision medicine and personalized cancer therapies rises, the regional market is poised to play a pivotal role in reshaping the landscape of cancer diagnosis and treatment over the forecasted period.

United States Liquid Biopsy Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2025-2033. Our report has categorized the market based on product and service, circulating biomarker, cancer type, and end user.

Product and Service Insights:

• Kits and Reagents
• Platforms and Instruments
• Services
   

The report has provided a detailed breakup and analysis of the market based on the product and service. This includes kits and reagents, platforms and instruments, and services.

Circulating Biomarker Insights:

• Circulating Tumor Cells
• Extracellular Vesicles
• Circulating Tumor DNA
• Others
   

A detailed breakup and analysis of the market based on the circulating biomarker have also been provided in the report. This includes circulating tumor cells, extracellular vesicles, circulating tumor DNA, and others.

Cancer Type Insights:

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Others
   

The report has provided a detailed breakup and analysis of the market based on the cancer type. This includes lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and others.

End User Insights:

• Hospitals and Laboratories
• Academic and Research Centers
• Others
   

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals and laboratories, academic and research centers, and others.

Regional Insights:

• Northeast 
• Midwest 
• South 
• West
   

The report has also provided a comprehensive analysis of all the major regional markets, which include Northeast, Midwest, South, and West. 

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

United States Liquid Biopsy Market Report Coverage:

Key Questions Answered in This Report:

• How has the United States liquid biopsy market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the United States liquid biopsy market?
• What is the breakup of the United States liquid biopsy market on the basis of product and service?
• What is the breakup of the United States liquid biopsy market on the basis of circulating biomarker?
• What is the breakup of the United States liquid biopsy market on the basis of cancer type?
• What is the breakup of the United States liquid biopsy market on the basis of end user?
• What are the various stages in the value chain of the United States liquid biopsy market? 
• What are the key driving factors and challenges in the United States liquid biopsy?
• What is the structure of the United States liquid biopsy market and who are the key players?
• What is the degree of competition in the United States liquid biopsy market?

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the United States liquid biopsy market from 2019-2033.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the United States liquid biopsy market.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the United States liquid biopsy industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.